logo-loader
viewZelira Therapeutics Ltd

Zelda Therapeutics poised to 'value add all the way from clinical trials to the market'

Dr Richard Hopkins, the newly appointed managing director of Zelda Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF), talks Proactive Investors through the medical cannabis researcher's recent strategic review, and provides updates on the company's three current clinical trials.

In its efforts to commercialise by bringing products to global markets as rapidly as possible, Zelda will focus on downstream integration, in contrast with many peer companies that are integrating upstream into cannabis cultivation.

Clinical trials are still at the centre of Zelda's operations. Currently there are trials ongoing for: opioid reducing pain management with St Vincent’s Hospital in Melbourne; insomnia with one of Australia’s leading sleep research centres; and paediatric patients with autism at the Children's Hospital of Philadelphia in the US.

Quick facts: Zelira Therapeutics Ltd

Price: 0.06 AUD

ASX:ZLD
Market: ASX
Market Cap: $57.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read